Krystal Biotech (KRYS) Capital Expenditures (2016 - 2026)

Krystal Biotech (KRYS) has 11 years of Capital Expenditures data on file, last reported at $7.1 million in Q1 2026.

• For the quarter ending Q1 2026, Capital Expenditures rose 15.22% year-over-year to $7.1 million; the trailing twelve-month figure through Mar 2026 stood at $4.0 million (down 70.16% YoY), and the FY2025 full-year result was $3.1 million, down 63.9% from the prior year.
• Capital Expenditures improved to $7.1 million in Q1 2026, from $2.4 million in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $22.2 million in Q2 2022 to a low of -$22.2 million in Q3 2022.
• A 5-year average of $2.5 million and a median of $2.4 million in 2025 frame the typical range for Capital Expenditures.
• Across the five-year window, Capital Expenditures plunged 232.55% in 2022 and soared 131933.33% in 2023, its largest moves.
• Tracing KRYS's Capital Expenditures over 5 years: stood at $14.9 million in 2022, then sank by 42.58% to $8.6 million in 2023, then tumbled by 40.85% to $5.1 million in 2024, then tumbled by 51.7% to $2.4 million in 2025, then surged by 192.47% to $7.1 million in 2026.
• Business Quant data shows KRYS's Capital Expenditures at $7.1 million in Q1 2026, $2.4 million in Q4 2025, and -$706000.0 in Q3 2025.